Neoplasma. 2016;63(5):774-8. doi: 10.4149/neo_2016_515.
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin lymphoma with adverse prognosis. It was demonstrated that alternation of CHOP and DHAP chemotherapy improved outcome of mantle cell lymphoma patients. However, which components of DHAP, cisplatin, cytarabine, or both, were responsible for the improved outcome remained unclear. To answer this question, antitumor efficacies of equally toxic doses of cytarabine, cisplatin, and three different combinations were compared in vivo using mouse xenograft models of mantle cell lymphoma. We demonstrated that cisplatin, alone or with cytarabine, is significantly superior to single-agent cytarabine in both eliminating lymphoma cells and suppressing their proliferation rate.
套细胞淋巴瘤是一种侵袭性 B 细胞非霍奇金淋巴瘤，预后不良。研究表明，CHOP 和 DHAP 化疗方案的交替使用改善了套细胞淋巴瘤患者的预后。然而，DHAP 中的哪些成分，顺铂、阿糖胞苷还是两者均有作用，仍不清楚。为了回答这个问题，我们使用套细胞淋巴瘤的小鼠异种移植模型，比较了同等毒性剂量的阿糖胞苷、顺铂和三种不同组合的药物的抗肿瘤疗效。结果表明，顺铂单独或与阿糖胞苷联合使用，在消除淋巴瘤细胞和抑制其增殖率方面均明显优于单药阿糖胞苷。
